PORTLAND, IA, UNITED STATES, January 9, 2025 /EINPresswire / -- The factors that are anticipated to impede the growth of the global nucleic acid therapeutics market during the forecast period include, ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Meiji Seika Pharma invests in MPM BioImpact's new technology and virology strategy to expand early-stage opportunities and ...

NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a ...

Professor Kevin J. Zwezdaryk and Chandler H. Monk discuss CRISPR and diagnostics, focusing on the development of a portable ...

Protein barcoding has emerged as a powerful tool for multiplexed protein selection, analysis, and tracking, enabling advanced insights into proteomics research. Traditional detection methods, such as ...

The UK Biobank project, announced today, aims to investigate how fluctuations in protein levels during mid- to late-life may influence <a target= ...

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter "Meiji") announced that the company has concluded an investment agreement wi ...

Maravai LifeSciences Holdings said Wednesday it expects to report full-year revenue for 2024 near the midpoint of its most recent outlook. The San Diego company has guided for full-year revenue ...

Adenosine deaminase 2 (ADA2) has been identified as a regulator of toll-like receptor 9 (TLR9) activation in response to nucleic acids, according to a recent study.

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks ...

Principal Financial Group Inc. lessened its stake in shares of Qiagen (NYSE:QGEN – Free Report) by 12.0% in the 3rd quarter, ...